Full-Year Results 2021/22 Arnd Kaldowski, CEO Birgit Conix, CFO Thomas Bernhardsgrütter, IR Stäfa, May 17, 2022 Disclaimer This presentation contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, ...

Financial Data and Key Metrics Changes - The company reported a growth of 29% for the year in local currency, with a two-year compound annual growth rate (CAGR) of 9.7% [13][47] - Adjusted EBITDA margin increased by 180 basis points in local currency, reaching 39.3% [26][49] - Earnings per share (EPS) adjusted increased by 38.7% to 10.76 [50] - Operating free cash flow rose by 26.8% to 764 million [50] Business Line Data and Key Metrics Changes - Hearing Instruments segment grew by 25.4%, with an organic growth rate of 23.4% year-over-year [29][41] - Cochlear Implants showed strong demand for new sound processors, regaining market share despite some supply chain headwinds [32][46] - Consumer Hearing segment faced challenges in the first month post-acquisition of Sennheiser, resulting in low revenue and negative EBITDA contribution [31] Market Data and Key Metrics Changes - The U.S. market was the fastest-growing region, with strong performance in the first half driven by pent-up demand [34] - All regions experienced growth in the second half, with rates between 14% to 16% [35] - The company noted that foot traffic in many markets was not as strong historically, leading to increased lead generation costs [27] Company Strategy and Development Direction - The company aims to continue driving growth initiatives while balancing margin expansion [11][15] - The acquisition of Sennheiser is expected to enhance consumer reach and expand the product offering from regular hearing aids to early hearing loss devices [12][66] - The company is focusing on innovation in Cochlear Implants and Hearing Instruments, with new product launches planned [18][19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing market recovery but noted that it is not fully realized yet, with challenges from supply chain issues and inflation [7][64] - The company expects sales growth of 17% to 21% year-over-year and EBITDA growth of 12% to 18% for the upcoming year [15][63] - Management remains optimistic about the strategic direction and believes the current strategy is effective [15][66] Other Important Information - The company achieved carbon neutrality last year and is committed to science-based targets for emissions [24][25] - A new three-year share buyback program of 1.5 billion was announced, following the completion of a previous 700 million buyback [51][60] Q&A Session Summary Question: About OTC hearing aids and market fundamentals - Management discussed the potential of hearable devices with speech enhancement, emphasizing a focus on this segment rather than traditional OTC devices [75][76] Question: Marketing spend for Sennheiser consumer business - Management indicated that while there is a ramp-up in marketing spend due to product launches, significant increases are not planned for the full year [79][80] Question: Sales and profitability performance in H1 vs H2 - Management noted that the second half is typically stronger due to seasonal factors and product cycles, with pent-up demand gradually normalizing [83][86] Question: Pricing strategies and challenges with large accounts - Management acknowledged that pricing adjustments are more challenging with large accounts like government contracts, which have fixed timelines for price changes [97][98]

Half-Year Results 2021/22 Arnd Kaldowski, CEO Birgit Conix, CFO Thomas Bernhardsgrütter, IR Stäfa, November 15, 2021 Disclaimer This presentation contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditi ...

Financial Data and Key Metrics Changes - Company reported sales of 1.6 billion Swiss francs, an increase of 48.5% year-over-year, with 46.6% attributed to organic growth [35] - EBITDA reached 406 million Swiss francs, reflecting a 129.3% increase compared to the previous year, with an EBITDA margin up 8.9 percentage points [36] - Adjusted EPS increased by 142%, reaching 4.86 Swiss francs compared to 1.97 Swiss francs in the prior year [42] Business Line Data and Key Metrics Changes - Hearing Instruments segment showed a two-year CAGR of 10.5%, with an EBITDA margin of 25.6% [22][27] - Audiological Care segment faced geographical headwinds, with a two-year CAGR of 6.3% [22] - Cochlear Implants segment achieved a 13% EBITDA margin, the highest ever for this segment, driven by strong sales from Marvel processors [21] Market Data and Key Metrics Changes - U.S. market demonstrated a strong performance with a 12.2% two-year CAGR, attributed to market share gains and pent-up demand [25][26] - EMEA markets showed slower recovery, particularly in Germany, Belgium, and the Netherlands, which were among the slowest markets [20] - Asia experienced weaker performance due to lockdowns in Japan, Australia, and New Zealand [26] Company Strategy and Development Direction - Company maintains its strategic focus on innovation and market share growth, particularly in Audiological Care and Hearing Instruments [13][17] - Plans to continue bolt-on acquisitions in Audiological Care, targeting 70 to 100 million Swiss francs in capital deployment annually [17] - Emphasis on R&D investment, with a two-year CAGR of 20.4% in R&D spending [43] Management's Comments on Operating Environment and Future Outlook - Management acknowledges ongoing challenges from COVID-19 and supply chain issues but remains optimistic about maintaining guidance for the full year [10][52] - Anticipates continued strong demand in the U.S. market, with expectations for a gradual slowdown in growth rates [55] - Management expects higher lead generation costs to persist in slower markets, with increases of 20-25% in some regions [74] Other Important Information - Company repurchased shares worth 277 million Swiss francs by September 30, contributing to a net debt position of 345 million Swiss francs [38] - Operating free cash flow increased by 37% to 337 million Swiss francs, reflecting a focus on working capital management [22] Q&A Session Summary Question: M&A strategy and potential assets - Management indicated interest in bolt-on acquisitions in Audiological Care and potentially larger assets if strategically attractive [63][65] Question: Gross margin sustainability amid supply chain pressures - Management acknowledged the need to consider inflation and microelectronics costs, suggesting potential for price adjustments in future innovation cycles [64][67] Question: EBITDA margin expectations amid processor upgrade revenue softening - Management expects to maintain double-digit EBITDA margins despite potential revenue declines in processor upgrades [71][73] Question: Lead generation cost increases - Lead generation costs have risen significantly, with some markets experiencing increases of 20-25% compared to pre-COVID levels [72][74] Question: U.S. market performance and growth segments - Management noted strong performance in the U.S. market, particularly in private-label contracts and VA, but highlighted slower growth in the VA segment [80][82] Question: Component cost impact on gross margin - Higher component costs impacted EBITDA by approximately 50 basis points in the first half, with expectations of 100-150 basis points in the second half [86][87] Question: Sennheiser Consumer Division performance - Sennheiser's business is performing well, with some increased costs due to component shortages, but no significant impact on sales [89]

Investor Presentation September 2021 Disclaimer This presentation contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competit ...

Sonova Holding AG (OTCPK:SONVF) Q4 2021 Earnings Conference Call May 18, 2021 7:00 AM ET Company Participants Thomas Bernhardsgrütter - Director, Investor Relations Arnd Kaldowski - Chief Executive Officer Hartwig Grevener - Chief Financial Officer Birgit Conix - Incoming Chief Financial Officer Conference Call Participants Patrick Wood - Bank of America Daniel Buchta - ZKB Veronika Dubajova - Goldman Sachs Oliver Metzger - Commerzbank David Adlington - JPMorgan Markus Gola - Stifel Christoph Gretler - Cred ...

Sonova Holding AG (OTCPK:SONVF) Q2 2021 Earnings Conference Call November 16, 2020 7:00 AM ET Company Participants Thomas Bernhardsgrütter - Director, Investor Relations Arnd Kaldowski - Chief Executive Officer Hartwig Grevener - Chief Financial Officer Conference Call Participants Daniel Buchta - Vontobel Patrick Wood - Bank of America Michael Jungling - Morgan Stanley Veronika Dubajova - Goldman Sachs Kit Lee - Jefferies Oliver Metzger - Commerzbank Markus Gola - Stifel Maja Pataki - Kepler Cheuvreux Chri ...

Media Release First half results 2020/21: Strong performance in light of market headwinds Stäfa (Switzerland), November 16, 2020 – Sonova Holding AG, a leading provider of hearing solutions, today announces its results for the first half of fiscal year 2020/21. Consolidated sales reached CHF 1,069.6 million, down 20.9% in local currencies or 25.0% in Swiss francs. While the development was adversely impacted by the COVID-19 pandemic, business activities picked up strongly over the course of the period with ...

15.42 0.30 0.30 15.42 Investor Presentation September 2020 HEAR THE WORLD Disclaimer This presentation contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, mark ...

Sonova Holding AG (OTCPK:SONVF) Q4 2020 Earnings Conference Call May 19, 2020 7:00 AM ET Company Participants | --- | --- | --- | |---------------------------------------------|-------|------------------------------------| | | | | | Arnd Kaldowski - CEO | | | | | | Hartwig Grevener - CFO | | | | Thomas Bernhardsgrutter - Head, IR | | | | Conference Call Participants | | | | Daniel Buchta - Vontobel | | Sebastian Walker - UBS Maja Pataki - Kepler | | | | | | Michael Jungling - Morgan Stanley | | Kit Lee - Je ...